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ABSTRACT
Background. Although trastuzumab (T) represents the stan-
dard of care for the adjuvant treatment of HER2-positive
early-stage breast cancer, contrasting results are available
about the cardiac toxicity associated to its use. We con-
ducted a multiregional population-based cohort investigation
aimed to assess both the short- and long-term cardiovascular
(CV) outcomes in women with early breast cancer treated
with T-based or standard adjuvant chemotherapy (CT).
Materials and Methods. We used health care use databases
of six Italian regions, overall accounting for 42% of the Italian
population. The study cohort was made by all women surgi-
cally treated for breast cancer who started a first-line adjuvant
T-based or CT treatment. Patients treated with T were 1:2 mat-
ched to those treated with CT based on date of treatment
start, age, and presence of CV risk factors. Short- and long-term
CV outcomes (heart failure and cardiomyopathy) were mea-
sured, respectively, after 1 year and at the end of follow-up.
Results. Among 28,599 women who met the inclusion criteria,
6,208 T users were matched to 12,416 CT users. After a mean
follow-up of 5.88 years, short- and long-term cumulative CV
risk were 0.8% and 2.6% in patients treated with T and 0.2%
and 2.8% in those treated with CT, respectively. Adjusted haz-
ard ratios were 4.6 (95% confidence interval [CI], 2.6–8.0) for
short-term and 1.2 (95% CI, 0.9–1.6) for long-term CV risk.
Discussion. In our large real-world investigation, T-associated
cardiotoxicity was limited to the treatment period. The addi-
tion of T to adjuvant CT did not result in long-term worsening
of CV events. The Oncologist 2020;25:e1492–e1499
Implications for Practice: Adjuvant trastuzumab-based chemotherapy represents the backbone therapy in patients with
HER2-positive early breast cancer. Although well tolerated, cardiovascular events can manifest during or after therapy
because of treatment-related toxicities. In this wide multicenter and unselected cohort, long-term symptomatic
cardiotoxicity was low and limited to the treatment period. The findings suggest that developing tools that would be ade-
quately able to predict cardiac toxicity at an early stage remains an important area in which additional research efforts are
needed.
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INTRODUCTION
Trastuzumab (Herceptin, Roche; Basel, Switzerland) was the
first humanized monoclonal antibody against the extracellu-
lar domain of HER2 approved in 1998 by the U.S. Food and
Drug Administration (FDA) in patients with HER2 over-
expressed and/or amplified (i.e., HER2-positive) metastatic
breast cancer [1, 2]. Later on, in 2006, adjuvant treatment
with 1 year of trastuzumab was also approved in patients
with HER2-positive early (localized) breast cancer [3, 4].
Given its well-documented efficacy in reducing recurrence
and death, as compared with standard chemotherapy alone,
trastuzumab became the standard of care for HER2-positive
breast cancer [5].
With longer survival, emphasizing overall health through
management of late and long-term treatment effects is
increasingly important. Trastuzumab is well tolerated; never-
theless, cardiovascular (CV) events, such as congestive heart
failure (CHF) or decreased left ventricular ejection fraction,
can manifest during or after therapy because of treatment-
related toxicities [6–8]. However, randomized clinical trials
(RCTs) [9] and observational studies [10] showed that cardiac
toxicity remains low and occurs mostly during the treatment
phase. Moreover, the results of two RCTs showed that CV
events were asymptomatic and reversible in most patients,
who reached recovery within than 6 months after stopping
therapy [11, 12]. Conversely, other observational studies
showed a prolonged risk of CV events, even after the treat-
ment stopped [13–15]. Therefore, CV safety in long-term sur-
vivors of adjuvant chemotherapy with or without trastuzumab
is still a debated issue, also because many of the studies with
trastuzumab have been carried out in selected patients,
whereas, at present, the drug has entered the vademecum of
oncologists for years and is offered on a large scale.
With these premises, a wide multiregional real-world
population-based cohort investigation was carried out to
compare short- and long-term cardiovascular risk of symp-
tomatic CV events in women with localized breast cancer
treated with trastuzumab-based or standard adjuvant ther-
apy in clinical practice. The study is a part of an Italian pro-
ject funded by the Italian Medicines Agency (Agenzia Italiana
del Farmaco) and the Health Department of the Sardinia
Region, which supported the Biological Drugs in Oncology
(Farmaci Biologici in Oncologia; FABIO) program.
MATERIALS AND METHODS
Data Sources
The Italian National Health Service (NHS) provides universal
and mostly free of charge health care services, including
medicines for cancer. The service is administered within each
of the 21 Italian regions by an automated system of health
care use (HCU) databases that collect a variety of informa-
tion, including at least (a) demographic and administrative
data on residents who receive NHS assistance (almost the
whole resident population); (b) hospital discharge records
providing information on primary diagnosis, coexisting condi-
tions, and procedures performed to inpatients admitted in
public and private hospitals and coded according to the
International Classification of Diseases, 9th Revision Clinical
Modification classification system; (c) drugs dispensed by ter-
ritorial pharmacies and medicines directly administered in
the outpatient setting and day-hospital coded according to
the Anatomical Therapeutic Chemical (ATC) classification sys-
tem; (d) data on outpatient services, including specialist visits,
laboratory tests, and diagnostic imaging; and (e) copayment
exemption database, including exemption for cancer, the latter
two both coded according to the National nomenclature.
Record linkage between databases is allowed through a single
identification code (Regional Health Code). To preserve pri-
vacy, each identification code is automatically converted into
an anonymous code, and the inverse process is prevented by
deletion of the conversion table.
The FABIO Network
The FABIO program was conducted by retrieving HCU data
from six Italian regions localized at Northern (Lombardy),
Central (Lazio and Marche), Southern (Abruzzo), and Insular
(Sardinia and Sicily) Italy. The corresponding resident popu-
lation overall accounts for about 25.5 million inhabitants,
representing 42.1% of the entire Italian population. A
detailed description of the procedure adopted from design-
ing, harmonizing and achieving regional cancer research
platforms is given in supplementary online Appendix 1.
Cohort Selection and Exposure Definition
During the recruitment period, in a time-span ranging
between 2007 and 2016 based on data availability of partic-
ipating regions, female NHS beneficiaries with an interven-
tion of breast surgery were selected. The date of the first
hospital admission for breast surgery was defined as the
“index date.” Among these patients, those who had a diag-
nosis of invasive breast cancer during the year before the
index date were included in the study cohort. Women were
excluded if they (a) already underwent breast surgery dur-
ing the year before the index date; (b) received a diagnosis
of secondary cancer, distant lymph nodes, or distant metasta-
ses during the year before or 6 months after the index date;
(c) received diagnosis of CHF or cardiomyopathy (i.e., the out-
comes of interest) in the 3 years before the index date;
(d) were younger than 18 years; (e) died during the index
hospitalization; or (f) did not receive drug therapy with
trastuzumab or standard chemotherapy within 6 months after
the index date. Specific diagnostic and therapeutic codes used
for the current study are given in supplemental online
Table 1.
The date of the first cancer drug dispensation after dis-
charge from the index hospitalization was defined as “treat-
ment start.” As trastuzumab is indicated for the treatment
of patients with early breast cancer in association or follow-
ing adjuvant chemotherapy [16], cohort members were
classified as exposed to trastuzumab (i.e., belonging to the
trastuzumab arm), or to standard chemotherapy alone
(i.e., belonging to the standard arm), according to whether
they received or not at least one trastuzumab dispensation
(ATC L01XC03) during the year following treatment start,
respectively.
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Outcome and Covariates
The endpoint of interest was the first hospitalization for CHF
or cardiomyopathy identified during follow-up. The admis-
sion date of the first hospitalization for these causes was
defined as the date of outcome onset. Several covariates
were assessed at index date for each cohort member, includ-
ing age, year of cohort inclusion, nodal status, type of sur-
gery (i.e., radical or conservative), and presence of CV risk
factors (i.e., diabetes, hypertension, cardiac arrhythmia, and
renal failure) recorded within 3 years before index date.
Matching Cohort Arms
To reduce the between-exposure arms heterogeneity, each
cohort member exposed to trastuzumab (index case) was
matched with two cohort members on standard chemo-
therapy alone. The latter were randomly selected from
those who started therapy at the same date of the index
case (30 days). Matching was based on age at surgical
intervention (1 year) and presence of at least one CV risk
factor. Then, in each 1:2 matched risk set, patients accumu-
lated person-years of follow-up from the date of the first
trastuzumab prescription of the index case until the out-
come onset, or censoring (death, emigration, or endpoint
of follow-up), whichever came first. As we were interested
in both short- and long-term effects of exposure to
trastuzumab, endpoint of follow-up was fixed at 1 year or
at the last date with data available within each region
(i.e. from December 31, 2016, to June 30, 2018, depending
on regional data availability), respectively.
Statistical Analysis
Between-arm differences in baseline characteristics were
tested by the χ2 statistics. The cumulative risk of occurrence
of CV events was estimated by using the Kaplan-Meier
(KM) estimator. The Gehan-Breslow-Wilcoxon test was used
for testing between-arm CV risk differences because it does
not require proportional hazards and gives more weight to
events at early time points [17, 18]. To increase the preci-
sion of the estimates, between-region summarized KM cur-
ves were estimated. However, as regional data were not
available to be analyzed in a pooled analysis, a method for
reconstructing individual-patient data starting from each
regional KM curve was applied. Briefly, a digital software
was used to read the coordinates of the KM curves within
each region. Information on the number of women still at
risk at each year of follow-up and the total number of out-
come events was used to solve the inverted KM equation,
which allowed for reconstructing the regional KM data for
each arm, thus obtaining pooled individual-patient data [19].
The associations between adjuvant treatment with
trastuzumab-based therapy and short-term or long-term
outcome occurrence were estimated by means of a Cox
proportional hazard model and expressed as hazard ratio
(HR), along with its 95% confidence interval (CI). As patients
treated with chemotherapy alone may have switched to
trastuzumab during follow-up, the exposure of interest was
considered as a dichotomous time-dependent covariate.
Beyond the exposure of interest, the model included nodal
status and type of surgery. Between-arm differences in
terms of age, CV risk factors, and date of treatment start
were intrinsically accounted for by the matched study
design. Again, to increase the precision of the estimates,
and because regional data were not available to be ana-
lyzed in a pooled analysis, the so-called two-stage meta-
analysis was performed [20]. Briefly, the proportional
hazard model was separately fitted within each region, and
between-region summarized HR was estimated by means of
Overall Lazio Marche Abruzzo Sardinia SicilyRegion
Patients who received breast surgery (index date) during the recruitment period 
Recruitment period 2007-2011 2012-2014 2011-2014 2015-2016 2011-2015
112,062 26,035 4,764 4,483 2,677 17,574
84,012 21,839 4,023 3,813 2,417 16,756
82,376 21,399 3,932 3,702 2,378 16,575
28,599 7,641 1,401 1,310 789 6,506
Patients with diagnosis of malignant early-stage breast cancer
Patients treated within 6 months from index date with either trastuzumab or conventional chemotherapy alone






Final 1:2 matched cohort
6,208 1,505 63 65 116 1,625








Figure 1. Flow-chart of inclusion and exclusion criteria for each participant region, as well as in the entire investigated population
© 2020 The Authors.
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a fixed-effect model, using the inverse variance weighting
[21]. Between-regions heterogeneity was evaluated by
using the χ2 statistics [22] and was measured through the I2
index [23], the latter measuring the percentage variation
across the regions due to heterogeneity.
In a secondary analysis limited to data from the Lom-
bardy Region (i.e., the largest Region among those included
in the FABIO program), the synergy between trastuzumab
and radiotherapy in increasing the risk of occurrence of CV
was assessed. Exposure to radiotherapy, evaluated in both
inpatient and outpatient setting, was considered as a time-
dependent covariate.
For all the tested hypotheses, two-tailed p values < .05
were considered statistically significant.
Ethical Issues
The Ethical Committee of the University of Milano-Bicocca eval-
uated the protocol and established that the study (a) was
exempt from informed consent (according to General
Figure 2. Kaplan-Meier estimates of the cumulative risk of hos-
pitalization for heart failure or cardiomyopathy in 6,208 and
12,416 breast cancer women on adjuvant therapy respectively
with T-based CT and CT alone.
Abbreviations: CT, standard chemotherapy; T, trastuzumab.
Figure 3. Forest plot of the summarized associations between trastuzumab-based adjuvant therapy and the short-term and long-
term risk of hospitalization for heart failure or cardiomyopathy, compared use of standard chemotherapy alone. Estimates are
shown for each participant region, and by summarizing region-specific hazard ratios.
Abbreviations: CI, confidence interval; CT, standard chemotherapy; IV, inverse variance; T, trastuzumab.
© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Trastuzumab Cardiotoxicity in Early Breast Cancere1496
Authorization for the Processing of Personal Data for Scientific
Research Purposes issued by the Italian Privacy Authority on
December 15, 2016; http://www.garanteprivacy.it/web/guest/
home/docweb/-/docweb-display/docweb/5805552),
(b) provides sufficient guarantees of individual records anonym-
ity, and (c) was designed according to quality standards of good
practice of observational research based on secondary data.
RESULTS
The process of selection of the study cohort in each partici-
pating region, as well as in all regions together, is reported
in Figure 1. Among the almost 112,062 patients who under-
went breast surgery identified during the study period
across all participating regions, 82,376 met the inclusion
criteria and constituted the study cohort. Of these, 28,599
women received a cancer drug therapy within 6 months
from the surgical intervention, of whom 6,728 (23.5%) had
trastuzumab-based therapy and 21,871 (76.5%) had stan-
dard chemotherapy alone. Finally, 6,208 trastuzumab users
were matched to 12,416 standard therapy users.
As shown in Table 1, matched patients had a median
age of 55 years and 37% prevalence of CV risk factors. Com-
pared with patients belonging to the standard arm, those
belonging to the trastuzumab arm were less likely to have a
positive nodal status (41% vs. 44%, p < .001) and to receive
a conservative surgery (64% vs. 69%, p < .001).
During a mean follow-up of 5.84 and 5.90 years,
109 (1.8%) and 199 (1.6%) cohort members experienced the
outcome among patients belonging to the trastuzumab arm
and standard arm respectively, with the corresponding long-
term incident rates 3.0 (95% CI, 2.4–3.6) and 2.7 (2.4–3.1)
every 1,000 women-years (p = .206). For short-term incidence
rates (i.e., by restricting the analysis only to the first years of
follow-up), the corresponding figures were 7.8 (5.6–10.0) and
1.9 (1.1–2.7) every 1,000 women-years (p < .001).
Different patterns in the cumulative CV outcomes were
observed according to therapeutic arm (Fig. 2). Women
belonging to the trastuzumab arm had a rapid increment of
heart failure or cardiomyopathy up to reach 0.8% during the
first year after starting therapy (i.e., during the expected
period of treatment with trastuzumab), whereas a lower
slope was observed from the second year on, until reaching
2.6% along the entire 8-year follow-up. Interestingly, among
the 109 CV outcomes experienced by patients on treatment
with trastuzumab, 48 (44%) occurred during the first year of
follow-up, and the remaining 61 occurred in the following
7 years. In contrast, in patients belonging to the standard
harm, the CV risk increased almost linearly during follow-up,
reaching figures of 0.2% and 2.8% after the first year of
follow-up and among the entire 8-year follow-up, respec-
tively. However, considering the entire follow-up, there was
no significant evidence of between-treatment differences in
the CV risk (p = .134). Region-specific KM curves are shown
in supplemental online Figure 1.
Forrest plots of region-specific and between-region
summarized HR of short-term (upper plot) and long-term
(lower plot) CV outcomes are shown in Figure 3. As far as
short-term effects are concerned (upper plot), there was no
evidence of between-region heterogeneity in HR (p = .43;
I2 = 0%). Summarized HR was 4.6 (95% CI, 2.6–8.0). As far
as long-term effects are concerned (lower plot), even in this
case there was no evidence of between-region heterogene-
ity in HR (p = .71; I2 = 0%), whereas summarized HR was 1.2
(95% CI, 0.9–1.6).
Secondary analysis showed that the proportion of
patients treated with radiotherapy was similar in the two
treatment arms (72.4% and 75.8%, respectively, in the
trastuzumab arm and in the standard arm, p < .001). Short-
term and long-term HRs were 2.38 (95% CI, 0.61–9.33) and
1.16 (95% CI, 0.71–1.92), respectively, for those treated
with radiotherapy, as compared with those who did not. No
interaction was found between trastuzumab and radiother-
apy treatment, neither related to short-term (p = .202) nor
to long-term (p = .239) CV risk assessment.
DISCUSSION
This Italian multiregional real-world study evaluated the
cardiotoxicity of trastuzumab adjuvant therapy for treating
early-stage breast cancer. The study suggests that women
treated with trastuzumab had high risk of hospitalization
for CHF and cardiomyopathy during the treatment period,
up to 4.6 times higher than women treated with standard
chemotherapy alone during the first year after the start of
drug treatment. Of note, the risk diminishes after the end
of treatment and becomes comparable to that of women
treated with standard chemotherapy alone after 8 years of
follow-up. These results are consistent with both RCTs [9,
11, 12] and observational studies [10, 24] that showed that
trastuzumab-based chemotherapy does not result in long-
term worsening of CV events.
As compared with observational studies, our retrospec-
tive cohort study showed a lower incidence of CV events.
Indeed, we estimated that women on treatment with
trastuzumab had 0.8% and 2.4% cumulative incidence of
heart failure and cardiomyopathy after 1 year and 8 years
of follow-up, respectively. Higher figures of 1.8% and 2.8%
after 1 and 3 years of follow-up were reported by a recent
Italian real-world study [10]. Endpoints considered by the
latter study, however, regarded myocardial infarction,
rhythm disorders, cardiac dysfunctions, and cardiac death,
other than heart failure and cardiomyopathy as in our
study. Similarly, 1 year and 8 years cumulative incidence of
CHF, respectively, of 3.0% and greater than 5% were
observed in a population-based Canadian study of women
who underwent surgery for breast cancer [24]. Endpoints
considered by this study, however, regarded both outpa-
tient and inpatient diagnoses of CHF, rather than the severe
CHF episodes leading to hospital admission as in our study,
likely generating an underestimate of the risk of CV events.
Other population-based observational studies have
raised concerns that trastuzumab-related cardiac toxicity in
routine practice may be greater than that seen in clinical
trials, especially in the elderly and in patients previously
exposed to anthracyclines. In particular, a nationwide Dan-
ish retrospective cohort study reported that, compared with
the CV risk of 6,695 patients treated with standard chemo-
therapy alone, that of 2,117 women treated with
trastuzumab-based therapy was increased 3.6-fold during
© 2020 The Authors.
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the first 18 months of observation and 1.9-fold in the fol-
lowing 18 months [13]. Similarly, a real-world study using
the U.S. SEER-Medicare database showed that patients with
breast cancer aged more than 67 years and treated with
trastuzumab with or without anthracyclines had a 78%
increased risk of CHF and cardiomyopathy compared with
patients treated with no adjuvant trastuzumab or chemo-
therapy during a 3-year follow-up (HR, 1.78; 95% CI,
1.43–2.21) [15]. Finally, a population-based retrospective
cohort study in the U.S. showed a linear trend of long-term
CV risk of patients both treated with trastuzumab only and
with trastuzumab plus anthracyclines during a 5.5 years
follow-up. In particular, cumulative incidence was 3.6%,
7.8%, and 12.1% after, respectively, 1, 3, and 5 years follow-
up in patients treated with trastuzumab only and 6.2%,
13.2%, and 20.1% in patients treated with trastuzumab plus
anthracyclines [14].
Our study has several strengths. First, the target popula-
tion from which we selected the final cohort was representa-
tive of the routine clinical practice in Italy. Indeed, all
beneficiaries of the NHS hospitalized with a diagnostic code
of breast cancer during the recruitment period were included
in the study, with no restrictions on age and concomitant dis-
eases. Moreover, participating regions covered approximately
42% of the Italian population and likely reflected the hetero-
geneity in clinical practice for treating breast cancer and car-
ing CV outcomes. Second, to the best of our knowledge, this
is the largest study performed so far on cardiotoxicity of
trastuzumab in terms of patients enrolled. Third, the median
follow-up was almost 6 years, with more than 15% of cohort
patients still at risk of experiencing a CV event after 8 years
of observation. This allowed studying cardiotoxicity associ-
ated to trastuzumab both during the treatment period and,
more importantly, during several years after ceasing the
treatment, giving important evidence on the reversibility of
the CV risk.
In contrast, the main limitation of the study is the paucity
of data on individual characteristics, clinical features and drug
patterns and regimens. Consequently, the increased CV risk
associated with trastuzumab might have been biased by fac-
tors influencing both chemotherapeutic regimen and out-
come onset. Factors such as ethnicity or socioeconomic
status can be confidently ruled out because the Italian popu-
lation is largely white, and free-of-pay access to cancer care is
ensured for all NHS beneficiaries. Furthermore, it is unlikely
that between-arm structural differences may affect CV risk
only during the period in treatment with trastuzumab. Finally,
our analyses were adjusted for nodal status and type of sur-
gery, which may be considered proxies of breast cancer stage.
Other unmeasured factors, however, might affect our find-
ings. For example, it is known that anthracyclines increase
the risk of congestive CHF [25] and that the harmful effect of
anthracyclines may be amplified when they are administered
in combination with trastuzumab [26]. In contrast, the Cana-
dian observational study cited above did not provide evidence
that the use of anthracyclines, at dosages used in the current
chemotherapy protocols for adjuvant breast cancer therapy,
increases the risk of CHF in patients treated with trastuzumab
[24]. In our study, we could not assess the combined effect of
anthracyclines and trastuzumab because anthracycline use
was not traceable from out HCU database. Other unintended
residual confounders (i.e., family history and smoking status)
could affect our findings. Moreover, data on asymptomatic
decline in left ventricular ejection fraction or symptomatic
CHF not requiring hospitalization were not available, because
our databases did not include details about physical examina-
tions, symptoms, blood tests (i.e., brain natriuretic peptide),
or echocardiography results.
CONCLUSION
In conclusion, our large real-world investigation offers further
evidence that trastuzumab-associated severe cardiotoxicity is
limited to the treatment period and that in breast cancer sur-
vivors, the addition of trastuzumab to adjuvant chemother-
apy does not result in long-term worsening of CV events.
Developing tools that would be adequately able to predict
cardiac toxicity at an early stage remains an important area
in which additional research efforts are needed. Therefore, in
view of the success of the treatment in terms of absolute sur-
vival, our results underline the importance of the collabora-
tion between oncologists and cardiologists to ensure optimal
care to women with breast cancer treated with cardiotoxic
agents.
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